Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- 1 December 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 12 (12), 1798-1805
- https://doi.org/10.1016/j.jtho.2017.08.022
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Toxicities of Immunotherapy for the PractitionerJournal of Clinical Oncology, 2015
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsAnnals Of Oncology, 2015
- Cancer Statistics, 2015CA: A Cancer Journal for Clinicians, 2014
- Reassessing target antigens for adoptive T-cell therapyNature Biotechnology, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2007